ALT
Altimmune IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$511.15M
P/E Ratio
—
EPS
$-1.00
Beta
0.34
52W High
$7.73
52W Low
$2.60
50-Day MA
$3.56
200-Day MA
$4.05
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.18
PEG Ratio
32.62
About Altimmune Inc
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | 41,000 |
| Gross Profit (TTM) | $-66.39M |
| EBITDA | $-94.38M |
| Operating Margin | -111127.00% |
| Return on Equity | -50.60% |
| Return on Assets | -28.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.03 |
| Price-to-Book | 2.26 |
| Price-to-Sales (TTM) | 12467.17 |
| EV/Revenue | 6573.15 |
| EV/EBITDA | 11.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 420.00% |
| Shares Outstanding | $194.35M |
| Float | $129.45M |
| % Insiders | 0.41% |
| % Institutions | 28.63% |
Historical Volatility
HV 10-Day
96.10%
HV 20-Day
78.62%
HV 30-Day
73.81%
HV 60-Day
72.47%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($18.15 target)
3
Strong Buy6
Buy1
Hold1
SellData last updated: 4/30/2026